Modality
Nanobody
MOA
KIF18Ai
Target
IL-13
Pathway
Fibrosis
Crohn'sBCC
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
~Aug 2018
→ ~Nov 2019
Phase 2
~Feb 2020
→ ~May 2021
Phase 3
~Aug 2021
→ ~Nov 2022
NDA/BLA
Feb 2023
→ Feb 2027
NDA/BLACurrent
NCT03685387
2,482 pts·BCC
2023-02→2026-03·Completed
NCT05074854
2,604 pts·Crohn's
2024-01→2027-02·Recruiting
5,086 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-03-241w agoPh3 Readout· BCC
2026-07-083mo awayBTD· Crohn's
2027-02-2811mo awayPh3 Readout· Crohn's
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
NDA/BLA
Complet…
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2026-03-24 · 1w ago
BCC
BTD
2026-07-08 · 3mo away
Crohn's
Ph3 Readout
2027-02-28 · 11mo away
Crohn's
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03685387 | NDA/BLA | BCC | Completed | 2482 | PASI75 |
| NCT05074854 | NDA/BLA | Crohn's | Recruiting | 2604 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 |